FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
Guggenheim reiterated a Buy rating and $40.00 price target on Horizon Pharma (NASDAQ: HZNP) following the company's 3Q15 earnings report. HZNP reported adjusted diluted 3Q15 EPS of $0.70, $0.29 above consensus. The company also raised its '15 EBITDA guidance to $350MM-$360MM from $265MM-$280MM, consensus was... More

